Family case study · Literature synthesis
My mother had bicuspid aortic valve disease and stenosis — lost to medical malpractice. My daughter was born with the same defect. That inheritance is why this work exists: to follow published NOTCH1 literature across congenital heart disease, neurodevelopment, and oncology — connecting dots specialty clinics often keep separate.
Not a claim of discovering a new gene. A disciplined walk through PubMed / PMC and peer-reviewed sources to surface cross-field links already in the record — so the next family is not left assembling the map alone.
Origin
This is personal. My mother had a bicuspid aortic valve with stenosis. She died because of medical malpractice. My daughter was born with the same defect — the same structural story, a generation later.
That is the hammer: bicuspid aortic valve disease is not an abstract PubMed topic in this house. It is my mother I lost, and my daughter I am raising with the same congenital valve problem. When NOTCH1 and related congenital heart genetics enter the picture, the stakes are not theoretical.
What stands out as I dig into the genetics is how often the published cross-field links that connect NOTCH1 beyond cardiology into neurodevelopment and oncology never surface for families in ordinary conversation — even when the papers already exist.
That gap is not a failure of any one clinician. It is a structural feature of how biomedical knowledge is partitioned: specialty silos, enormous citation volume, and limited time to read outside one’s field. After losing a mother to preventable medical failure, and then watching the same valve defect appear in a daughter, waiting for someone else to assemble the map was not enough. Pathfinder began as a disciplined walk through those adjacent literatures — using only published sources — so families like ours can see what already exists in the record.
Approach
Start from established congenital heart disease genetics — notably Garg et al., Nature (2005), which linked NOTCH1 mutations to aortic valve disease and severe vascular anomalies — then expand outward through cited and citing work.
Query PubMed and PubMed Central (~39 million+ citations in the biomedical corpus) for NOTCH1 intersections with neurodevelopment, autism spectrum phenotypes, and cancer biology — reading abstracts and full text where available.
Use AI and large language models to help triage papers, extract claimed associations, and organize citation graphs — always as a draft map, never as a substitute for the primary literature.
Every finding below is tied to a citable preprint or journal article. Where evidence is preliminary (e.g., Research Square preprints), that status is stated. Nothing here invents mechanisms or clinical conclusions.
Published record
The following points summarize what appears in the published literature we reviewed. They are not clinical recommendations.
A 2025 Research Square preprint reports a multi-omics analysis highlighting NOTCH1, PTPN11, and SMAD4 among hub genes connecting congenital heart disease and autism spectrum disorder pathways.
Research Square rs-8108414/v1 (Dec 2025, preprint — not peer-reviewed journal publication).
Parallel preprint work examines Notch signaling in autism spectrum disorder model systems, situating developmental Notch dysregulation among candidate neurodevelopmental mechanisms under study.
Research Square rs-6343474/v1 (April 2025, preprint).
Tuand et al. reported that Neurobeachin (NBEA) — implicated in neurodevelopmental phenotypes — interacts with NOTCH1 and modulates Notch signaling, providing a molecular bridge discussed in the neurobiology literature.
Tuand et al., PLOS ONE (2016). doi:10.1371/journal.pone.0145663
Population studies report elevated autism spectrum disorder risk among children with congenital heart disease — on the order of roughly twofold relative risk, with prevalence estimates around 9.1% in some cohorts and median age at ASD diagnosis near 34 months in published samples.
Pediatrics (2019); Cardiology in the Young (2023). See also related CHD–neurodevelopmental outcome literature.
NOTCH1 is extensively documented in cancer biology as context-dependent — acting with oncogenic or tumor-suppressor roles depending on tissue and lesion type. MedlinePlus Genetics and PMC reviews summarize this dual character; it is part of why oncology literature sits adjacent to developmental Notch work.
MedlinePlus Genetics (NOTCH1); peer-reviewed reviews indexed in PMC. This page does not interpret any individual’s cancer risk.
Map
Three literatures meet at one gene. The diagram is a navigation aid — not a pathway claim.
Rationale
PubMed and PMC hold on the order of 39 million+ citations. No specialist can read across cardiology, developmental neuroscience, and oncology for every gene that appears in a clinical report. A father who has already lost his mother to a valve defect — and is raising a daughter with the same anatomy — is rarely handed a cross-field literature map either.
Cross-referencing does not replace clinical care. It does not undo malpractice. It can, however, help researchers and informed families ask better questions: Which adjacent literatures already discuss this gene? Which associations are peer-reviewed versus preprint? What remains hypothesis, and what is established genetics?
For NOTCH1, the published record already spans heart, brain, and cancer biology. Making that adjacency visible is the point of this case study — and of Pathfinder as a broader literature-navigation idea. My family is the reason I built it.
Boundaries
Next
Pathfinder is the working name for literature-synthesis tooling that helps researchers and families navigate cross-field citation maps — starting from cases like mine: the same congenital valve defect across generations, and a gene (NOTCH1) where the science already exists in fragments across silos.
Interested in the approach, collaboration, or early access conversations?
hello@crosspathfinder.com